

Independent Auditor's Review Report on Unaudited Quarterly and Year to Date Standalone Financial Results of Transpek Industry Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To the Board of Directors,
Transpek Industry Limited**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Transpek Industry Limited** ("the Company") for the quarter ended December 31, 2025 and for the year to date period from April 1, 2025 to December 31, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) 34, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **BANSI S. MEHTA & CO.**
Chartered Accountants
Firm Registration No. 100991W



A handwritten signature in blue ink, appearing to be "P.H.", followed by a long horizontal line and a large, stylized flourish on the right side.

PARESH H. CLERK
Partner
Membership No. 036148
UDIN : 26036148WJAXCJ8070

PLACE : Mumbai
DATED : February 4, 2026

Independent Auditor's Review Report on Unaudited Quarterly and Year to Date Consolidated Financial Results of Transpek Industry Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To the Board of Directors,
Transpek Industry Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Transpek Industry Limited** ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended December 31, 2025 and for the year to date period from April 1, 2025 to December 31, 2025 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the management of the Holding Company and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) 34, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entity:

Name of the Entity	Relationship
Transpek Creative Chemistry Private Limited	Wholly owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **BANSI S. MEHTA & CO.**
Chartered Accountants
Firm Registration No. 100991W



PARESH H. CLERK

Partner

Membership No. 036148

UDIN : 26036148PVHPOJ4490

PLACE : Mumbai

DATED : February 4, 2026

Ph #: (0265) 6700300

TRANSPEK INDUSTRY LIMITED
 Regd. Office : 4th Floor, Lillieria 1038, Gotri-Sevasi Road, Vadodara - 390021
 website: www.transpek.com email: secretarial@transpek.com
STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

₹ in Lakhs

Particulars	Standalone						Consolidated					
	Quarter Ended		Nine Months Ended		Year Ended		Quarter Ended		Nine Months Ended		Year Ended	
	December 31, 2025 (Unaudited)	September 30, 2025 (Unaudited)	December 31, 2024 (Unaudited)	December 31, 2025 (Unaudited)	December 31, 2024 (Unaudited)	March 31, 2025 (Audited)	December 31, 2025 (Unaudited)	September 30, 2025 (Unaudited)	December 31, 2024 (Unaudited)	December 31, 2025 (Unaudited)	December 31, 2024 (Unaudited)	March 31, 2025 (Audited)
I Revenue from Operations	15,847.79	16,027.24	17,003.94	47,296.36	45,459.66	64,995.31	15,847.79	16,027.24	17,003.94	47,296.36	45,459.66	64,995.31
II Other Income	354.12	502.88	489.36	2,023.13	2,098.47	2,870.78	354.12	502.88	489.36	2,023.13	2,098.47	2,870.78
III Total Income (I+II)	16,201.91	16,530.12	17,493.30	49,319.49	50,556.13	67,856.09	16,201.91	16,530.12	17,493.30	49,319.49	50,556.13	67,856.09
IV Expenses												
a. Cost of Materials Consumed	6,430.52	7,617.50	9,204.10	21,737.86	24,675.30	33,032.69	6,430.52	7,617.50	9,204.10	21,737.86	24,675.30	33,032.69
b. Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-progress	404.29	(363.80)	(862.33)	98.54	47.38	213.73	404.29	(363.80)	(862.33)	98.54	47.38	213.73
c. Employee Benefits Expense	1,917.58	1,813.76	1,725.01	5,562.92	5,076.75	6,662.82	1,917.58	1,813.76	1,725.01	5,562.92	5,076.75	6,662.82
d. Finance Costs	166.72	241.11	312.49	653.58	895.13	1,174.31	166.72	241.11	312.49	653.58	895.13	1,174.31
e. Depreciation and Amortisation Expense	1,234.03	1,233.99	1,213.27	3,899.88	3,734.97	4,996.93	1,234.03	1,233.99	1,213.27	3,899.88	3,734.97	4,996.93
f. Other Expenses	4,522.28	4,291.21	4,563.14	12,332.44	12,413.15	15,807.68	4,522.41	4,291.25	4,563.25	12,332.66	12,413.46	15,808.06
Total Expenses (IV)	14,755.42	14,833.47	16,135.88	44,085.22	46,842.68	61,690.16	14,755.55	14,833.51	16,135.79	44,085.45	46,843.01	61,690.54
V Profit / (Loss) before Exceptional Items and Tax (III-IV)	1,446.49	1,696.65	1,357.42	5,234.27	3,713.45	6,165.93	1,446.36	1,696.61	1,357.51	5,234.04	3,713.12	6,165.55
VI Exceptional Items	-	-	-	-	-	-	-	-	-	-	-	-
VII Profit / (Loss) before Tax (V+VI)	1,446.49	1,696.65	1,357.42	5,234.27	3,713.45	6,165.93	1,446.36	1,696.61	1,357.51	5,234.04	3,713.12	6,165.55
VIII Tax Expense												
a. Current Tax	391.00	413.00	430.00	1,321.00	1,030.00	1,670.00	391.00	413.00	430.00	1,321.00	1,030.00	1,670.00
b. Deferred Tax	(28.86)	19.75	(112.04)	8.88	(240.44)	(353.16)	(28.86)	19.75	(112.04)	8.88	(240.44)	(353.16)
c. Excess / (Short) Provision for tax of earlier years	(0.34)	-	(25.01)	(0.34)	(25.01)	(24.98)	(0.34)	-	(25.01)	(0.34)	(25.01)	(24.98)
Total Tax Expense	361.80	432.75	292.95	1,329.54	764.55	1,291.86	361.80	432.75	292.95	1,329.54	764.55	1,291.86
IX Net Profit / (Loss) for the period (VII-VIII)	1,084.69	1,263.90	1,064.47	3,904.73	2,948.90	4,874.07	1,084.56	1,263.86	1,064.56	3,904.50	2,948.57	4,873.69
X Other Comprehensive Income												
Items that will not be reclassified to profit or loss												
a. Remeasurement gain / (loss) on defined benefit plans	35.79	(76.32)	(51.21)	(46.06)	(153.64)	(22.12)	35.79	(76.32)	(51.21)	(46.06)	(153.64)	(22.12)
b. Effect of measuring Equity Instruments at Fair Value	(336.25)	275.78	(4,394.07)	384.06	5,204.78	761.61	(336.25)	275.78	(4,394.07)	384.06	5,204.78	761.62
c. Income tax on above	39.08	(20.22)	641.24	(43.46)	1,633.78	2,361.58	39.08	(20.22)	641.24	(43.46)	1,633.78	2,361.57
Total Other Comprehensive Income	(261.38)	179.24	(3,804.04)	295.44	6,684.92	3,101.07	(261.38)	179.24	(3,804.04)	295.44	6,684.92	3,101.07
XI Total Comprehensive Income for the period (IX+X)	823.31	1,443.14	(2,739.57)	4,200.17	9,633.82	7,975.14	823.18	1,443.10	(2,739.48)	4,200.96	9,633.49	7,974.76

de B. Mehta



TRAN SPEK INDUSTRY LIMITED

Regd. Office : 4th Floor, Lilleria 1638, Gotri-Sevasi Road, Vadodara - 390021

Ph # : (0265) 6700300

website: www.transpek.com


email: secretarial@transpek.com

STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

₹ in Lakhs

Particulars	Standalone						Consolidated						
	Quarter Ended			Nine Months Ended			Quarter Ended			Nine Months Ended			Year Ended
	December 31, 2025 (Unaudited)	September 30, 2025 (Unaudited)	December 31, 2024 (Unaudited)	December 31, 2025 (Unaudited)	December 31, 2024 (Unaudited)	March 31, 2025 (Audited)	December 31, 2025 (Unaudited)	September 30, 2025 (Unaudited)	December 31, 2024 (Unaudited)	December 31, 2025 (Unaudited)	December 31, 2024 (Unaudited)	March 31, 2025 (Audited)	
XII Paid up Equity Share capital (Face Value ₹ 10 each)	558.58	558.58	558.58	558.58	558.58	558.58	558.58	558.58	558.58	558.58	558.58	558.58	
XIII Other Equity						73,975.01						73,973.34	
XIV Earnings per share of ₹ 10 each (not annualised):													
Basic (₹)	19.42	22.62	19.06	69.94	52.79	87.26	19.42	22.62	19.06	69.94	52.79	87.25	
Diluted (₹)	19.42	22.62	19.06	69.94	52.79	87.26	19.42	22.62	19.06	69.94	52.79	87.25	
See accompanying notes to the Financial Results													

- Notes :
- The above results which are published have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 4, 2026. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results. The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
 - The Company is engaged in the business of manufacturing of "Chemicals", which is the only Operating Segment as per Ind AS 108.
 - On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment subsequently published draft Central Rules and FAQs to enable assessment of the financial impact arising from the revised regulatory framework. Accordingly, the Company assessed the impact of these changes and based on the information available as of date, certain estimates and actuarial valuation, has made an incremental provision towards Gratuity of ₹ 137.32 lakhs under the head "Employee Benefits Expense" in the Statement of Unaudited Financial Results for the quarter and nine months ended December 31, 2025. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Codes and would provide appropriate accounting effect on the basis of such developments as needed.
 - Consolidated Financial Results include result of a wholly owned subsidiary, namely, Transpek Creative Chemistry Private Limited.

For TRAN SPEK INDUSTRY LIMITED

 BIMAL V. MEHTA
 MANAGING DIRECTOR
 DIN: 00081171
 DATE: February 4, 2026
 PLACE: Vadodara

